血必净注射液及其组分羟基红花黄色素A对脓毒症大鼠凝血与生存率影响的比较
该研究在盲肠结扎穿孔(CLP)诱导的脓毒症大鼠中,比较血必净注射液(4 mL/kg,每日两次,尾静脉)与其组分羟基红花黄色素A(0.378 g/L,每次298 μg,每日两次,尾静脉)对凝血指标和7天生存率的影响。凝血评估每组36只:与假手术组相比,CLP组6小时即出现凝血功能障碍并随时间加重;两种干预均使6小时凝血指标改善(P<0.01),但两干预组间无显著差异。生存分析每组30只:CLP组7天累积生存率36.67%(11/30),血必净组和羟基红花黄色素A组均为66.67%(20/30),均高于CLP组(P<0.05),两干预组间无显著差异。作者认为两者均能有效减轻脓毒症大鼠凝血紊乱并提高生存率。
要点
- 脓毒症大鼠CLP后6小时即出现凝血功能障碍:PT延长(8.9±0.2 s vs. 假手术组8.4±0.4 s,P<0.01),且12小时后进一步加重。
- 血必净(4 mL/kg,每日两次,尾静脉)与羟基红花黄色素A(0.378 g/L,每次298 μg,每日两次,尾静脉)均使6小时PT缩短至8.3±0.2 s和8.3±0.1 s(vs. CLP组8.9±0.2 s,均P<0.01)。
- 两干预均降低6小时Fib、D-二聚体、TFPI和sTM(均P<0.01),但血必净组与羟基红花黄色素A组之间凝血功能无显著差异。
- 7天累积生存率:CLP组36.67%(11/30),血必净组66.67%(20/30),羟基红花黄色素A组66.67%(20/30);两干预组均高于CLP组(均P<0.05),两干预组间无显著差异。
- 假手术组大鼠术后7天全部存活。
适用人群与场景
- 雄性Sprague-Dawley(SD)大鼠,采用盲肠结扎穿孔(CLP)复制脓毒症模型。
- 凝血评估部分144只,每组36只;生存分析部分120只,每组30只。
- 假手术组开腹暴露盲肠后还纳腹腔,不进行CLP,其余步骤同CLP组。
处置流程与药物剂量
- CLP+血必净组:术后经尾静脉注射血必净4 mL/kg,每日两次。
- CLP+羟基红花黄色素A组:术后经尾静脉注射羟基红花黄色素A溶液(0.378 g/L),每次298 μg,每日两次。
- 分别于术后6、12、24小时用自动凝血分析仪检测外周血PT、APTT、TT、Fib、D-二聚体,用酶联免疫吸附试验(ELISA)检测TF、TFPI、sTM。
研究设计与关键结果
- 研究类型:动物实验(脓毒症大鼠模型),比较血必净注射液与其组分羟基红花黄色素A对凝血和生存率的影响。
- 凝血评估(每组36只):与假手术组相比,CLP组6小时PT延长(s:8.9±0.2 vs. 8.4±0.4,P<0.01),Fib、D-二聚体、TFPI、sTM升高[Fib(g/L):2.8±0.3 vs. 2.3±0.1;D-二聚体(ng/L):1.8±0.2 vs. 1.5±0.1;TFPI(ng/L):131.1±10.9 vs. 102.8±10.5;sTM(μg/L):27.2±1.2 vs. 19.8±2.9;均P<0.01];12小时凝血功能障碍加重并随时间进一步恶化。
- 6小时两干预组与CLP组比较:PT缩短(s:血必净组8.3±0.2、羟基红花黄色素A组8.3±0.1 vs. CLP组8.9±0.2,均P<0.01);Fib降低(g/L:2.3±0.1、2.3±0.2 vs. 2.8±0.3,均P<0.01);D-二聚体降低(ng/L:1.5±0.1、1.5±0.2 vs. 1.8±0.2,均P<0.01);TFPI降低(ng/L:109.5±10.2、91.5±5.0 vs. 131.1±10.9,均P<0.01);sTM降低(μg/L:22.3±1.5、21.1±1.8 vs. 27.2±1.2,均P<0.01);两干预组间凝血功能无显著差异。
- 生存分析(每组30只):假手术组7天全部存活;CLP组7天累积生存率36.67%(11/30);血必净组66.67%(20/30)、羟基红花黄色素A组66.67%(20/30)均高于CLP组(均P<0.05);两干预组间无显著差异。
证据类型、等级与局限
- 证据类型:动物实验(SD大鼠CLP脓毒症模型)。
- 作者结论:血必净及其组分羟基红花黄色素A似乎均能有效减轻脓毒症大鼠凝血紊乱并提高生存率,两者效应无显著差异。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文为动物实验,作者认为血必净及其组分羟基红花黄色素A似乎均能减轻脓毒症大鼠凝血紊乱并提高生存率,两者效应无显著差异。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To explore the effects of Xuebijing injection and its component hydroxysafflor yellow A on coagulation and survival rates of septic rats.
METHODS: (1) Assessment of coagulation: 144 male Sprague-Dawley (SD) rats were divided into four groups by random number table: sham group, cecal ligation and puncture (CLP) induced sepsis model group (CLP group), CLP+Xuebijing group, and CLP+hydroxysafflor yellow A group, with 36 rats in each group. CLP was used for reproducing septic models. The cecum of the rats in the sham group was exposed by laparotomy and then returned to the abdominal cavity without CLP, while the other steps were the same as those in the CLP group. Rats in the CLP+Xuebijing group and CLP+hydroxysafflor yellow A group were injected with Xuebijing (4 mL/kg, twice a day) or hydroxysafflor yellow A solution (0.378 g/L, 298 μg each time, twice a day) through caudal vein after operation. Levels of prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT), fibrinogen (Fib), and D-dimer in peripheral blood were measured by automatic coagulation analyzer at 6, 12, 24 hours after operation. The enzyme linked immunosorbent assay (ELISA) was applied to determine levels of tissue factor (TF), tissue factor pathway inhibitor (TFPI), and soluble thrombomodulin (sTM) in peripheral blood. (2) Analysis of survival rates: 120 rats were divided into four groups by random number table (the same groups with those in the section of assessment of coagulation), with 30 rats in each group. The Kaplan-Meier survival curve was plotted, and the cumulative survival rates were observed and recorded for 7 days after CLP surgery.
RESULTS: (1) Results of coagulation assessment: compared with the sham group, septic rats in the CLP group showed significant dysfunction in coagulation early, as evidenced by prolonged PT at 6 hours after CLP (s: 8.9±0.2 vs. 8.4±0.4, P < 0.01), and significantly increased levels of Fib, D-dimer, TFPI and sTM [Fib (g/L): 2.8±0.3 vs. 2.3±0.1, D-dimer (ng/L): 1.8±0.2 vs. 1.5±0.1, TFPI (ng/L): 131.1±10.9 vs. 102.8±10.5, sTM (μg/L): 27.2±1.2 vs. 19.8±2.9, all P < 0.01]. The coagulation dysfunction became more and more serious at 12 hours after operation, and further deteriorated with time. The use of both Xuebijing and hydroxysafflor yellow A revealed significant improvement in coagulation of septic rats at 6 hours, as shown by shortened PT (s: 8.3±0.2, 8.3±0.1 vs. 8.9±0.2, both P < 0.01), and decreased Fib, D-dimer, TFPI and sTM as compared with those in the CLP group [Fib (g/L): 2.3±0.1, 2.3±0.2 vs. 2.8±0.3; D-dimer (ng/L): 1.5±0.1, 1.5±0.2 vs. 1.8±0.2; TFPI (ng/L): 109.5±10.2, 91.5±5.0 vs. 131.1±10.9; sTM (μg/L): 22.3±1.5, 21.1±1.8 vs. 27.2±1.2; all P < 0.01]. However, there was no significant difference in coagulation function between the two intervention groups. (2) Results of survival rates analysis: the rats in the sham group all survived 7 days after operation. The 7-day cumulative survival rate of the CLP group was only 36.67% (11/30). Compared with the CLP group, the cumulative survival rates were significantly increased in rats of the CLP+Xuebijing group and CLP+hydroxysafflor yellow A group [66.67% (20/30), 66.67% (20/30) vs. 36.67% (11/30), both P < 0.05], but no significant difference was found between the CLP+Xuebijing group and CLP+hydroxysafflor yellow A group.
CONCLUSIONS: Both Xuebijing and its component hydroxysafflor yellow A appear to be capable of alleviating coagulation disorders and improving survival rates of septic rats effectively, and the effects show no significant difference between them.
参考来源
- Ren C, Yao R, Wang L, et al. [Comparison of effects of Xuebijing injection and its component hydroxysafflor yellow A on coagulation and survival rates of septic rats]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2021. PMID: 34955128. doi:10.3760/cma.j.cn121430-20210225-00291
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。